Tech Company Financing Transactions
APT Pharmaceuticals Funding Round
On 7/21/2005, APT Pharmaceuticals announced $6 million in Series A investment from CLS and RCT BioVentures.
Transaction Overview
Company Name
Announced On
7/21/2005
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series A
Investors
CLS (Lead Investor) (Martin Sanders)
Proceeds Purpose
The proceeds of this financing will fund the initial Phase II clinical trial of the company's lead compound, an inhaled version of hydroxychloroquine (HCQ), for the treatment of asthma.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
700 Airport Blvd. 350
Burlingame, CA 94010
USA
Burlingame, CA 94010
USA
Phone
Website
Email Address
Overview
APT Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing products to treat asthma, chronic pulmonary obstructive disease, rhinitis and rhinovirus.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Dilly
Chief Operating Officer
Howie Raff
Chief Technical Officer
Ralph Niven
VP - Finance
Joe Melvin
VP - General Counsel
Christina Thomson
VP - Regulatory Affairs
Sue Barrowcliffe
Browse more venture capital transactions:
Prev: 7/21/2005: Farecast venture capital transaction
Next: 7/25/2005: Pertrac venture capital transaction
Share this article
Where The Data Comes From
We document funding rounds that are announced publicly. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs